Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric Cancer
Status:
Available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
- To determine the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT) of
sorafenib in combination with FOLFOX4 (oxaliplatin/leucovorin/5-fluorouracil) as
first-line treatment for advanced gastric cancer
- The design of the study incorporated a standard 3 + 3 dose escalation procedure to guide
elevation of the sorafenib dosage to the next level